Tell us about your model and your targets
Tell us the species, the targets, the dose groups and where the programme is heading. We will tell you which assays cover your markers in that species, whether cross-reactivity needs checking, and how to design the work so the method carries into first-in-human.
We will reply within one working day.
WHY IT MATTERS
Preclinical biomarker work makes three demands that discovery does not.
Preclinical biomarker work has three particular demands, and they are what distinguish it from discovery.
Across species
The same biological target may need measuring in animal models and later in human samples, with enough confidence to interpret what translates and what was species-specific. An assay that works beautifully in mouse and has no human equivalent has told you very little about your drug.
Across phases
The analytical method used preclinically should carry into clinical work wherever possible, so results stay comparable as the programme advances. Changing method between preclinical and clinical introduces a variable you then have to defend.
Under scrutiny
Target engagement, pharmacodynamic, safety and toxicology endpoints may contribute to regulatory-relevant decisions and need analytical documentation to match.
What works preclinically should be built to travel.
WHat we measure
Match the assay to the preclinical question
Murine and preclinical species profiling
Target engagement and pharmacodynamics
Toxicology and safety endpoints
Bridging to the clinic
Targets with no assay
Where we fit
Applications
Built to bridge mouse and human
The costliest preclinical mistake is not an assay that fails. It is an assay that works – but measures something with no human equivalent, or uses a method you cannot run on clinical samples.
Both problems can be avoided at the design stage. Both are hard to fix later.
Same platform, both sides of the transition
We run NULISAseq panels for both mouse and human samples, covering the same inflammation and neurology biology. Because the chemistry, readout and analysis stay the same, any difference between your preclinical and clinical results is far more likely to be real biology than a change in method.
Cross-reactivity checked before you commit
For custom assays, we check at the feasibility stage whether the antibodies work in both species. You find out before preclinical validation, not after.
The team stays with the programme
The same scientists who run your preclinical work stay on for the clinical phase. No handover, no new supplier to brief when the stakes are highest.
Why you can trust this now
The practical detail
Turnaround
Two weeks from sample receipt, confirmed at quote. Custom development quoted separately by phase
Quote
Sample confirmation
Sample volume
Matrices
Cross-species assessment
Regulated work
Quality framework
The research journey
From animal model to first-in-human, without switching laboratories.
02
Preclinical Development
Current stage
Target engagement, pharmacodynamic biomarkers, toxicology endpoints, and translational bridging from in vitro through to first-in-human.
03
Translational & Clinical Research
Validated biomarker workflows for clinical trial endpoints, regulatory-grade bioanalysis, patient stratification, and longitudinal monitoring.
Explore